After six years of jousting, Novartis (NVS) appears close to settling a lawsuit in which the federal government alleged the drug maker used kickbacks to doctors — including fishing trips and lavish meals — in order to boost prescriptions of several medicines, according to sources familiar with the matter.
There is no guarantee that a deal will occur. A trial date was set for this coming Monday in a Lower Manhattan courtroom, although a pretrial conference that was scheduled for last Friday was adjourned the previous day, according to court documents. Details of a settlement could not be learned, but sources indicate the company may agree to pay close to $1 billion to resolve the case. A spokeswoman for the U.S. Attorney in New York declined to comment, as did a Novartis spokesman.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
